CRITICAL PATH INSTITUTE STICHTING

Their core work

Critical Path Institute (C-PATH) is the European arm of a US-based non-profit organization that specializes in pre-competitive consortium science to accelerate drug and medical product development. Their core work involves building shared scientific tools — biomarkers, clinical outcome assessments, data standards, and analytical frameworks — that pharmaceutical companies and regulators can use together to reduce the cost and time of bringing treatments to market. In the H2020 portfolio, they contribute to tuberculosis drug regimen development (ERA4TB) and to establishing international measurement standards for patient-reported outcomes in clinical trials (SISAQOL-IMI). Their value lies in bridging academic research, industry R&D, and regulatory agencies such as the FDA and EMA.

What they specialise in

How they've shifted over time

C-PATH entered the H2020 programme with a focus squarely on infectious disease drug development — specifically tuberculosis, preclinical modeling, and the science of combining drugs into effective treatment regimens. As their participation progressed into the early 2020s, the focus shifted toward clinical measurement methodology: how outcomes are defined, reported by patients, and then analyzed in trials. This is not a departure from their core mission but a broadening — from "how do we develop better drugs" toward "how do we measure whether drugs work in a way regulators and clinicians will trust." The trajectory suggests growing engagement with clinical trial design and outcomes science beyond any single disease area.

C-PATH appears to be expanding from disease-specific drug development science into cross-therapeutic data and measurement standards — making them an increasingly relevant partner for any clinical programme that needs defensible patient-centered endpoints.

How they like to work

C-PATH participates exclusively as a consortium partner and has not led any H2020 project, which is consistent with their model of joining large pre-competitive consortia where they contribute specialized scientific infrastructure rather than managing projects. Despite only two projects, they have accumulated 68 unique partners across 19 countries — an unusually wide network suggesting they engage in large, multi-stakeholder programmes rather than small bilateral collaborations. This makes them a well-connected specialist node: they bring credibility, regulatory relationships, and methodological tools, and in return gain access to the data and clinical networks the consortium provides.

With 68 unique consortium partners across 19 countries from just two projects, C-PATH operates in large, multinational research programmes typical of IMI and Innovative Medicines Initiative funding structures. Their network is European in formal structure but likely extends to North America given C-PATH's US headquarters and existing FDA/EMA relationships.

What sets them apart

C-PATH occupies a rare position as a non-profit pre-competitive science organization — they are not a university, not a pharma company, and not a regulator, but they work at the intersection of all three. This neutrality is their primary asset: they can convene competing companies around shared scientific problems without commercial conflict of interest. For consortium builders in drug development, infectious disease, or clinical outcomes, C-PATH brings not just expertise but institutional credibility with regulatory bodies that few academic partners can match.

Highlights from their portfolio

• ERA4TB
  A major 6-year RIA programme (2020–2026) with EUR 1.86M in EC funding to C-PATH, targeting the development of new tuberculosis treatment regimens — one of the highest-priority global health challenges identified by WHO.
• SISAQOL-IMI
  An IMI-funded initiative establishing international consensus standards for patient-reported outcome analysis in clinical trials, with potential to shape regulatory expectations across multiple disease areas globally.